Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more
Scientific production - Institute for Cancer Research
In a recent publication in Annals of Oncology (journal impact factor 11.9) by Jørgen Smeby and colleagues in the Lothe lab at the Department of Molecular Oncology, integration of gene expression-based subtyping and microsatellite instability status led to discovery of novel subtype-specific prognostic associations of the thoroughly investigated KRAS and BRAFV600E mutations in primary colorectal cancer (CRC).
Jon Amund Kyte, leader of the "Translational cancer immunotherapy" project group at the Department of Cancer Immunology at the Institute for Cancer Research, was appointed "Researcher of the Month" for February 2018 by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). The group aims to develop improved cancer treatment based on two particularly promising strategies for immunotherapy. This research is presented in a feature article published on the home page of Helse Sør-Øst.
Global Engage has interviewed Guro E. Lind, group leader at the Department of Molecular Oncology.
"In order to achieve gender balance we should focus on why the system is failing recruiting the brilliant young female scientists, rather than discuss what the females should do to increase their chances of a scientific career. It is nothing wrong with our education, skill set or ambitions - it is the system that is flawed"
The Epigenetics Group at the Department of Molecular Oncology, headed by Guro E. Lind, has developed a robust internal control for DNA methylation analyses by droplet digital PCR (ddPCR). The findings have recently been published in the journal Clinical Epigenetics. First author is Heidi Dietrichson Pharo.